Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Regeneron Pharmaceuticals and Sanofi are conducting a study titled A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma. The study aims to evaluate the effectiveness of Dupilumab in preventing or slowing lung function decline in adults with uncontrolled moderate to severe asthma, highlighting its potential significance in improving patient outcomes.
The intervention being tested is Dupilumab, an injectable drug administered subcutaneously every two weeks after an initial loading dose. It is designed to treat asthma by reducing inflammation and improving lung function.
This interventional study is randomized with a parallel assignment model, and it employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on December 16, 2021, with an estimated primary completion date in 2025. The last update was submitted on August 7, 2025, indicating ongoing recruitment and progress.
The study’s findings could significantly impact Regeneron and Sanofi’s stock performance by potentially enhancing their asthma treatment portfolio. This could influence investor sentiment positively, especially in comparison to competitors in the respiratory treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.